Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Combination treatment with a selective androgen receptor modulator q(SARM) and a bisphosphonate has additive effects in osteopenic female rats.

Vajda EG, Hogue A, Griffiths KN, Chang WY, Burnett K, Chen Y, Marschke K, Mais DE, Pedram B, Shen Y, van Oeveren A, Zhi L, López FJ, Meglasson MD.

J Bone Miner Res. 2009 Feb;24(2):231-40. doi: 10.1359/jbmr.081007.

2.

Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator.

Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, O'Brien Z, Chang WY, Meglasson MD, Lee YH.

J Pharmacol Exp Ther. 2009 Feb;328(2):663-70. doi: 10.1124/jpet.108.146811. Epub 2008 Nov 18.

4.

Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.

Kimoto A, Tanaka M, Nozaki K, Mori M, Fukushima S, Mori H, Shiroya T, Nakamura T.

Bone. 2013 Jul;55(1):189-97. doi: 10.1016/j.bone.2013.02.013. Epub 2013 Feb 26.

PMID:
23486179
5.

Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats.

Ke HZ, Crawford DT, Qi H, Pirie CM, Simmons HA, Chidsey-Frink KL, Chen HK, Jee WS, Thompson DD.

Bone. 1999 Jan;24(1):41-7.

PMID:
9916783
7.

Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis.

Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N.

Biol Pharm Bull. 2003 Nov;26(11):1563-9.

8.

Bisphosphonate tiludronate increases bone strength by improving mass and structure in established osteopenia after ovariectomy in rats.

Ohnishi H, Nakamura T, Narusawa K, Murakami H, Abe M, Barbier A, Suzuki K.

Bone. 1997 Oct;21(4):335-43.

PMID:
9315337
10.

[Effects of bisphosphonates on the mechanical efficiency of normal and osteopenic bones].

Ferretti JL, Cointry GR, Capozza RF, Mondelo N, Peluffo V, Chiappe A, Meta M, Alippi RM.

Medicina (B Aires). 1997;57 Suppl 1:83-92. Spanish.

PMID:
9567360
11.

A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats.

Iwaniec UT, Moore K, Rivera MF, Myers SE, Vanegas SM, Wronski TJ.

Osteoporos Int. 2007 Mar;18(3):351-62. Epub 2006 Nov 22.

PMID:
17120182
12.

A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.

Armamento-Villareal R, Sheikh S, Nawaz A, Napoli N, Mueller C, Halstead LR, Brodt MD, Silva MJ, Galbiati E, Caruso PL, Civelli M, Civitelli R.

J Bone Miner Res. 2005 Dec;20(12):2178-88. Epub 2005 Aug 1.

13.
15.

Additive protective effects of estrogen and androgen treatment on trabecular bone in ovariectomized rats.

Tivesten A, Movérare-Skrtic S, Chagin A, Venken K, Salmon P, Vanderschueren D, Sävendahl L, Holmäng A, Ohlsson C.

J Bone Miner Res. 2004 Nov;19(11):1833-9. Epub 2004 Aug 23.

16.

Assessment of maintenance therapy with reduced doses of PTH(1-34) in combination with a raloxifene analogue (LY117018) following anabolic therapy in the ovariectomized rat.

Hodsman AB, Watson PH, Drost D, Holdsworth D, Thornton M, Hock J, Bryant H, Fraher LJ.

Bone. 1999 May;24(5):451-5.

PMID:
10321904
17.

Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats.

Prakasam G, Yeh JK, Chen MM, Castro-Magana M, Liang CT, Aloia JF.

Bone. 1999 May;24(5):491-7.

PMID:
10321909
18.

Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.

Martel C, Picard S, Richard V, Bélanger A, Labrie C, Labrie F.

J Steroid Biochem Mol Biol. 2000 Sep;74(1-2):45-56.

PMID:
11074355
19.

Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2.

Otomo H, Sakai A, Ikeda S, Tanaka S, Ito M, Phipps RJ, Nakamura T.

J Bone Miner Metab. 2004;22(5):404-14.

PMID:
15316861
20.

A comparison of the effects of two anabolic agents (fluoride and PTH) on ash density and bone strength assessed in an osteopenic rat model.

Søgaard CH, Mosekilde L, Thomsen JS, Richards A, McOsker JE.

Bone. 1997 May;20(5):439-49.

PMID:
9145241
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk